Tremelimumab (Imjudo) for Metastatic NSCLC
The Medical Letter on Drugs and Therapeutics · 2023
DOI: 10.58347/tml.2023.1669h ↗Kurz gefasst
Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, 2023. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms.
Abstract (Originalsprache)
The FDA has approved tremelimumab-actl (Imjudo – AstraZeneca), a cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) blocking antibody, for use in combination with the programmed death-ligand 1 (PD-L1) blocking antibody durvalumab (Imfinzi) and platinum-based chemotherapy for treatment of metastatic non-small cell lung cancer (NSCLC) in adults with no sensitizing epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) genomic tumor aberrations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Zitieren
APA
(2023). Tremelimumab (Imjudo) for Metastatic NSCLC. The Medical Letter on Drugs and Therapeutics. https://doi.org/10.58347/tml.2023.1669h
Vancouver
Tremelimumab (Imjudo) for Metastatic NSCLC. The Medical Letter on Drugs and Therapeutics. 2023. doi:10.58347/tml.2023.1669h
BibTeX
@article{euvimed2023,
title = {Tremelimumab (Imjudo) for Metastatic NSCLC},
journal = {The Medical Letter on Drugs and Therapeutics},
year = {2023},
doi = {10.58347/tml.2023.1669h}
}
EUVIMED